2025-12-12 23:04:20
Latest Post
KEC International wins New Orders of Rs. 1,150 crores
Emagia Convenes Global Summit to Explore the Next Wave of AI in Enterprise Finance
Lemon Tree Hotels signs a new property in Punjab
L T Elevator Ltd approves purchase of Commercial Land
Hindustan Zinc saves over 1 lakh GJ of energy in FY25; enough to power nearly 19,000 households annually
Stock Report
Dr. Reddy's Laboratories announces Science-Based Net Zero Climate Targets
Posted On : 2025-12-12 14:09:35( TIMEZONE : IST )
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy's"), today announced its Net Zero with near-term and long-term science-based emissions reduction targets, approved by the Science Based Targets initiative (SBTi).
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY2045. In the near term, the company commits to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 80%, and Scope 3 emissions by 51.6% per INR value added by FY2030, using FY2023 as the base year. In the long term, it commits to reducing absolute Scope 1, 2, and 3 emissions by 90% by FY2045, again from the FY2023 baseline. Dr. Reddy's is the only company in India's pharmaceutical sector to commit to a science-based Net Zero target by FY2045.
In October 2020, Dr. Reddy's announced its near-term SBTi targets. Based on its current progress and in line with its continued commitment to sustainability, the company has now revised its goals to Net Zero, with both near-term and long-term targets, in accordance with the latest SBTi Framework.
Sanjay Sharma, Global Head Operations and Chief Human Resources Officer, Dr. Reddy's Laboratories said: "As an early adopter of sustainability, we have consistently advanced through thoughtful and impactful climate actions. With a forward-looking vision, we are committed to achieving Net Zero by FY2045, reflecting both ambition and accountability towards our planet. Guided by sciencebased targets, we strive to align with global climate goals and set the benchmark for the pharmaceutical sector."
"Additionally, we are on track to achieve coal- and furnace oil-free operations by the end of FY'26, and with 68% of our power in FY'25 sourced from renewables, we are demonstrating the tangible impact of our climate actions on the ground," added Sanjay.
